Study of TQB3702 tablets for lupus
Part of Immune system & allergy, Skin clinical trials.
This study tests an oral tablet (TQB3702) for people with lupus. It aims to see if the drug can help control lupus activity. It's for patients already on standard lupus treatments with stable disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 70 years old
- Have had a lupus diagnosis for at least 6 months
- Be on a stable lupus treatment plan (like steroids or other meds) for at least 30 days before starting
- Have positive antibodies related to lupus (like ANA or anti-dsDNA)
- Not have severe kidney or brain problems from lupus, active infections, other autoimmune diseases, or certain recent treatments or vaccines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine, TQH3906, in people with systemic lupus erythematosus (SLE) who have moderate to severe disease activity. It aims to see if TQH3906 can safely reduce lupus symptoms like joint pain, skin rash, or vasculitis.
This study tests a new medicine called E6742 to help people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. Researchers want to see if this drug can reduce lupus symptoms and disease activity.
This study tests a new drug called LBL-047 in healthy people and in people with mild to moderate lupus. It helps check if the drug is safe and how the body processes it. Participating may help find better treatments for lupus.
This trial tests a new treatment, UB-VV410, for people with active systemic lupus erythematosus (SLE) or lupus nephritis (kidney inflammation caused by lupus) that hasn't responded to standard treatments. It aims to see if this therapy can help control the disease.
This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.
This trial tests an investigational drug called QLS4131 in people with active systemic lupus erythematosus (SLE) who are already on standard treatments. The goal is to see if adding QLS4131 can help control lupus activity better.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.